Latest Period
Q1 2026
Security Snapshot
Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) Institutional Ownership
CUSIP: 09627Y109
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026
Institutions Reporting
2
Shares (Excl. Options)
301
Price
$128.59
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- BPMC
- Shares outstanding
- 65,000,000
- Price per share
- $128.59
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 301
- Total reported value
- $38,583
- % of total 13F portfolios
- 0%
- Share change
- -25,583
- Value change
- -$2,535,546
- Number of holders
- 2
- Price from insider filings
- $128.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- BPMC - Blueprint Medicines Corp - Common Stock, par value $0.001 per share is tracked under CUSIP 09627Y109.
- 2 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $2,574,129 to $38,583.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 2 institutions filings for Q1 2026.
Security key
09627Y109
Latest holder period
Q1 2026
13F holders
2
13D/G owners
6
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09627Y109:
Significant Owners of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8% | $438,260,343 | 5,090,723 | BlackRock, Inc. | 31 Mar 2025 | |||
| Pentwater Capital Management LP | 6% | $501,345,000 | 3,900,000 | Pentwater Capital Management LP | 30 Jun 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | $264,580,914 | 3,073,306 | Wellington Management Group LLP | 31 Mar 2025 | |||
| FMR LLC | 3.5% | $193,502,643 | 2,247,679 | FMR LLC | 31 Dec 2024 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.3% | $188,330,378 | 1,465,036 | T. Rowe Price Associates, Inc. | 30 Jun 2025 | |||
| Avoro Capital Advisors LLC | 0.6% | -90% | $48,206,250 | -$446,711,250 | 375,000 | -90% | Avoro Capital Advisors LLC | 30 Jun 2025 |
As of 31 Mar 2026, 2 institutional investors reported holding 301 shares of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC). This represents 0% of the company’s total 65,000,000 outstanding shares.
Institutional Holders of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 301 | $38,583 | -$2,535,546 | $128.59 | 2 |
| 2025 Q4 | 25,884 | $2,574,129 | -$1,079,310 | $114.22 | 2 |
| 2025 Q3 | 26,105 | $2,576,619 | -$8,229,873,403 | $128.79 | 5 |
| 2025 Q2 | 64,312,805 | $8,243,642,810 | -$128,604,537 | $128.18 | 351 |
| 2025 Q1 | 68,515,184 | $6,063,993,897 | +$140,099,025 | $88.51 | 348 |
| 2024 Q4 | 67,115,861 | $5,854,192,362 | +$126,899,926 | $87.22 | 336 |
| 2024 Q3 | 65,318,958 | $6,043,433,303 | -$164,062,764 | $92.50 | 315 |
| 2024 Q2 | 66,328,149 | $7,149,236,804 | +$48,438,893 | $107.78 | 302 |
| 2024 Q1 | 65,816,848 | $6,243,787,913 | +$177,301,995 | $94.86 | 278 |
| 2023 Q4 | 64,072,815 | $5,910,035,943 | -$46,573,724 | $92.24 | 255 |
| 2023 Q3 | 64,715,958 | $3,250,100,220 | +$14,323,141 | $50.22 | 217 |
| 2023 Q2 | 63,590,792 | $4,019,089,438 | +$55,157,380 | $63.20 | 216 |
| 2023 Q1 | 63,289,977 | $2,844,730,700 | +$37,372,534 | $44.99 | 211 |
| 2022 Q4 | 62,710,123 | $2,747,307,504 | -$81,340,704 | $43.81 | 217 |
| 2022 Q3 | 63,026,048 | $4,152,774,974 | -$128,845,752 | $65.89 | 225 |
| 2022 Q2 | 63,150,127 | $3,190,446,271 | +$153,165,037 | $50.51 | 217 |
| 2022 Q1 | 59,787,423 | $3,819,690,831 | -$49,008,451 | $63.88 | 230 |
| 2021 Q4 | 58,954,217 | $6,315,932,336 | -$30,886,672 | $107.11 | 268 |
| 2021 Q3 | 59,635,260 | $6,131,078,115 | +$116,842,275 | $102.81 | 277 |
| 2021 Q2 | 58,476,330 | $5,143,894,117 | -$35,068,728 | $87.96 | 271 |
| 2021 Q1 | 58,503,342 | $5,692,147,794 | +$110,589,775 | $97.23 | 253 |
| 2020 Q4 | 57,620,842 | $6,462,000,707 | +$68,838,444 | $112.15 | 271 |
| 2020 Q3 | 56,891,234 | $5,271,748,149 | +$134,477,194 | $92.70 | 233 |
| 2020 Q2 | 56,241,583 | $4,386,082,844 | +$150,414,585 | $78.00 | 227 |
| 2020 Q1 | 54,500,343 | $3,186,566,973 | +$193,923,003 | $58.48 | 203 |
| 2019 Q4 | 50,739,129 | $4,064,646,435 | -$62,842,415 | $80.11 | 221 |
| 2019 Q3 | 51,436,764 | $3,779,091,159 | +$139,996,789 | $73.47 | 212 |
| 2019 Q2 | 49,572,751 | $4,675,884,768 | +$324,726,215 | $94.33 | 217 |
| 2019 Q1 | 48,530,965 | $3,884,677,938 | +$226,884,588 | $80.05 | 200 |
| 2018 Q4 | 45,667,665 | $2,458,997,783 | -$75,489,962 | $53.91 | 157 |
| 2018 Q3 | 44,853,567 | $3,501,103,825 | +$29,002,258 | $78.06 | 186 |
| 2018 Q2 | 44,815,573 | $2,844,822,168 | +$140,175,140 | $63.48 | 177 |
| 2018 Q1 | 41,175,457 | $3,775,678,943 | +$79,685,163 | $91.70 | 173 |
| 2017 Q4 | 42,824,142 | $3,229,416,996 | +$311,339,150 | $75.41 | 166 |
| 2017 Q3 | 36,265,378 | $2,526,591,713 | +$26,629,111 | $69.67 | 134 |
| 2017 Q2 | 35,562,415 | $1,801,945,033 | +$78,990,151 | $50.67 | 123 |
| 2017 Q1 | 34,688,336 | $1,387,181,269 | +$416,751,429 | $39.99 | 133 |
| 2016 Q4 | 26,029,473 | $730,115,893 | +$172,572,667 | $28.05 | 101 |
| 2016 Q3 | 19,170,288 | $569,347,585 | +$16,106,841 | $29.70 | 87 |
| 2016 Q2 | 19,506,647 | $394,921,156 | +$32,946,791 | $20.25 | 82 |
| 2016 Q1 | 17,896,943 | $323,004,000 | -$4,071,216 | $18.05 | 70 |
| 2015 Q4 | 17,994,524 | $473,980,234 | +$22,327,835 | $26.34 | 72 |
| 2015 Q3 | 23,905,839 | $509,238,942 | +$16,095,105 | $21.34 | 70 |
| 2015 Q2 | 23,164,184 | $611,154,430 | +$610,026,412 | $26.49 | 70 |